A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE2
GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)
- Status
- COMPLETED
- Phase
- PHASE3
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- Status
- RECRUITING
- Phase
- PHASE2
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402
- Status
- COMPLETED
- Phase
- N/A
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL
- Status
- COMPLETED
- Phase
- PHASE1
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis
- Status
- COMPLETED
- Phase
- PHASE4
Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma
- Status
- COMPLETED
- Phase
- N/A
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Intensified Rituimab Prephase Before FCR in Untreated B-CLL
- Status
- COMPLETED
- Phase
- PHASE2
Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2